Table 2. Univariate survival analyses (n=176).
Characteristics | OS (CI) | P-valuea | HR (CI) |
---|---|---|---|
Age, years | |||
⩽64 | 13.7 (10.0–17.4) | 0.52 | 0.90 (0.64–1.25) |
>64 |
13.9 (10.3–17.6) |
|
|
Sex | |||
Female | 12.0 (8.2–15.9) | 0.54 | 0.88 (0.58–1.33) |
Male |
13.9 (10.7–17.2) |
|
|
Histology | |||
Epithelioid | 14.6 (10.5–18.7) | <0.01 | 2.01 (1.31–3.10) |
Non-epithelioid |
6.5 (2.9–10.1) |
|
|
Stageb | |||
Early stage | 18.6 (0–39.8) | 0.01 | 2.09 (1.17–3.76) |
Late stage |
12.8 (9.7–15.9) |
|
|
Treatment | |||
Best supportive care | 6.5 (3.8–9.3) | <0.01 | 2.81 (1.75–4.51) |
Chemo- and/or radiotherapy | 12.6 (8.7–16.5) | 2.03 (1.33–3.10) | |
Multimodality treatment including radical surgery |
30.9 (12.9–48.9) |
|
1 |
Fibrinogen | |||
High fibrinogen | 8.5 (6.2–10.7) | <0.01 | 2.11 (1.49–2.99) |
Low fibrinogen | 19.1 (14.5–23.7) |
Abbreviations: CI=confidence interval; HR=hazard ratio; OS=overall survival.
Two-sided log-rank test.
Missing cases: n=26 (14.8%).